Overview Fundamentals Financials Technicals Corporate Action Shareholding Pattern Peer Comparison News Stock Analysis About Company FAQs

Concord Biotech Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

NSE: CONCORDBIO Small Cap ISIN: INE338H01029
As on 22 January 2025 at 15:42 IST
As on 22 January 2025 at 15:42 IST
2,120.55
-39.90
(-1.85%)
About Concord Biotech Ltd

Concord Biotech Ltd is a research and development-driven biopharmaceutical company. It specializes in manufacturing Active Pharmaceutical Ingredients (APIs). The company operates in the biotechnology sector. Concord Biotech has established itself as a significant player in the industry. The company was founded in the year 2000, which makes it decades old. The headquarters of Concord Biotech Ltd is located in Ahmedabad, Gujarat. The company's main product includes APIs and finished formulations for various therapeutic areas. These products are essential for treating various medical conditions and are widely used in the industry. Read More...

Over 1 Month
1.15%
Over 6 Months
29.91%
Over 1 Year
54.70%
Over 3 Years
0%

Concord Biotech Ltd Summary

Close ₹ 2,120.55
Open ₹ 2,160.45
High ₹ 2,163.50
Low ₹ 2,095
Volume 55,846
Net Turnover (in ₹) ₹ 76,86,97,575.95
52Wk High ₹ 2,664
52Wk Low ₹ 1,327.05
52Wk High / Low
1,327.05
2,664

Concord Biotech Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 22,601.81
EPS (TTM) 31.42
Book Value (BV) 152.04
Div. Yield 0.41 %
P/E (TTM) 68.72
Price/Book Value 14.20
Delivery % 84.70 %
Face Value 1

Key Ratios

PE Ratio 52.25
PB Ratio 10.44
EV to Sales 15.62
PEG Ratio 1.87
ROA 19.83
ROE 21.63
Debt-Equity 0.01
Net Profit Margin 29.97
Operating Profit Margin 45.82

Concord Biotech Ltd Financials

Profit and Loss

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2020FY 2019
Total Revenue1,050.72888.48736.35543.70-
Total Expenses641.53568.42495.19330.21-
Profit Before Tax412.56322.01237.52213.64-
Profit After Tax308.10240.09174.93169.11-
Operating Profit after Depreciation411.75324.56246.64214.19-

Balance Sheet

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2020FY 2019
Fixed Assets575.32592.98572.98239.60-
Total Non Current Assets804.48786.28680.13401.93-
Total Current Assets896.23727.70632.67538.79-
TOTAL ASSETS1,700.711,513.981,312.79940.73-
Total Shareholder's Fund1,526.651,2901,103.22770.23-

Cash Flow

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2020FY 2019
Net Cash from Operating Activities265.47246207.47155.09-
Net Cash used in Investing Activities-154.61-157.95-111.79-113.93-
Net Cash used in Financing Activities-99.21-85.22-100.16-42.52-

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Total Revenue1,050.72888.48736.35630.75543.70
Total Expenses641.53568.42495.19317.58330.21
Profit Before Tax409.19320.05241.16313.17213.49
Profit After Tax304.73238.13178.57235.33168.96
Operating Profit after Depreciation411.75324.56246.64313.83214.19

Balance Sheet

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Fixed Assets575.32592.98572.98546.22239.60
Total Non Current Assets803.08786.95680.79575.70401.78
Total Current Assets896.23727.70632.67607.15538.79
TOTAL ASSETS1,699.321,514.651,313.461,182.84940.58
Total Shareholder's Fund1,525.251,291.981,107.16999.67770.08

Cash Flow

Particulars (in ₹ Cr.) FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash from Operating Activities265.47246207.47166.81154.94
Net Cash used in Investing Activities-154.61-157.95-111.79-195.20-113.78
Net Cash used in Financing Activities-99.21-85.22-100.1631.12-42.52

Particulars (in ₹ Cr.) 2024-09 2024-06 2024-03 2023-12 2023-09
Total Revenue310.18215.80318.97240.80262.35
Total Expenses176.47134.52186.88134.86146.62
Profit Before Tax130.3379.52128.72103.11109.72
Profit After Tax95.7459.5995.0277.5781.02
Operating Profit after Depreciation143.7492.94142.90117.15123.86

Particulars (in ₹ Cr.) 2024-09 2024-06 2024-03 2023-12 2023-09
Total Revenue310.18215.80318.97240.80262.35
Total Expenses173.51134.52184.68134.86143.15
Profit Before Tax133.2978.17130.92100.09113.19
Profit After Tax98.7058.2497.2174.5584.49
Operating Profit after Depreciation146.7091.59145.10114.13127.33

Concord Biotech Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3
S1 2,131.35
S2 2,102.25
S3 2,054.50
Pivot 2,179.10
R1 2,208.20
R2 2,255.95
R3 2,285.05

Moving Average

20 SMA 2,201.30
50 SMA 2,117.30
100 SMA 2,031.08
200 SMA 1,799.50

Concord Biotech Ltd Corporate Actions

Concord Biotech Ltd

₹8.75/Share

Announcement Date 21 Jun 2024
Record Date 22 Jun 2024
Div Yield 875%

Concord Biotech Ltd Peer Comparison

Company Price Market Cap (in ₹ Cr)
Concord Biotech Ltd ₹2,159.30 ₹22,589.78
Sun Pharmaceuticals Industries Ltd ₹1,761.80 ₹4,22,714.84
Divis Laboratories Ltd ₹5,818.40 ₹1,54,460.24
Cipla Ltd ₹1,427.30 ₹1,15,270.75
Dr Reddys Laboratories Ltd ₹1,288.45 ₹1,07,511.36
Torrent Pharmaceuticals Ltd ₹3,157.60 ₹1,06,862.73

Concord Biotech Ltd News

Concord Biotech to conduct board meeting

On 11 November 2024

06 Nov 2024, 09:53 am

Volumes jump at Concord Biotech Ltd counter

Concord Biotech Ltd clocked volume of 19.99 lakh shares by 14:14 IST on NSE, a 33.61 times surge over two-week average daily volume of 59477 shares

29 Aug 2024, 02:30 pm

Concord Biotech schedules board meeting

On 9 August 2024

31 Jul 2024, 02:25 pm

Concord Biotech to conduct AGM

On 29 June 2024

31 May 2024, 04:57 pm

Volumes spurt at Concord Biotech Ltd counter

Concord Biotech Ltd notched up volume of 48.54 lakh shares by 14:14 IST on NSE, a 66.43 fold spurt over two-week average daily volume of 73078 shares

28 May 2024, 02:30 pm

Concord Biotech Ltd Stock Analysis

  1. Annual revenue for Concord Biotech Ltd increased by 18.26% to ₹1,050.72 crore in FY 2024 from ₹888.48 crore in FY 2023.
  2. Annual Net Profit for Concord Biotech Ltd increased by 27.97% to ₹304.73 crore in FY 2024 from ₹238.13 crore in FY 2023.
  3. Promoter Shareholding in Concord Biotech Ltd remains unchanged by 0.00% in the most recent quarter, from 44.08% in June 2024 to 44.08% in September 2024.
  4. Concord Biotech Ltd delivered a 1-year return of 54.70% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
  5. Concord Biotech Ltd share price moved down by 1.85% from its previous close of INR ₹2,160.45. The latest Concord Biotech Ltd share price is INR ₹2,120.55.
  6. Concord Biotech Ltd share price today has been at a low of 2,095 and a high of 2,163.50. Over the past 52 weeks, the Concord Biotech Ltd share price has seen a low of 1,327.05 and a high of 2,664.

About Concord Biotech Ltd

Concord Biotech Ltd is a research and development-driven biopharmaceutical company. The company manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes. It also produces finished formulations to meet diverse healthcare needs. The company’s products cater to various therapeutic segments, including oncology and anthelmintics.

Operating in the biotechnology sector, Concord Biotech has established itself as a significant player in the industry. The company was founded in 2000, making it decades old. Over the years, Concord Biotech has evolved into a broad-spectrum solution provider. It now offers a wide range of products across diversified therapeutic segments.

The headquarters of Concord Biotech Ltd is located in Ahmedabad, Gujarat. This strategic location enables the company to manage its operations and logistics efficiently. It ensures timely delivery of products to customers across the globe. The company's promoters include Sudhir Vaid, with a 28.84% stake. A team of professional promoters manages the operations of the company-
  • Ankur Vaid
  • Ravi Kapoor
  • Rajiv Ambrish Agarwal
  • Bharti Khanna

Concord Biotech’s main products include APIs and finished formulations for therapeutic areas. These areas include immunosuppressants, oncology, antifungals, antibacterials, and anthelmintics. These products are essential for treating various medical conditions and are widely used in the pharmaceutical industry. The company’s commitment to quality and innovation has helped it maintain a competitive edge in the market.

While Concord Biotech is not currently the number one stock in its sector, however, it holds a significant position in the biotechnology industry. The company continues to expand its market share, positioning itself as a strong contender in the industry.

Concord Biotech Ltd is poised for continued growth and success in the biotechnology sector, driven by its innovative products and commitment to quality. The promoter shareholding in Concord Biotech is substantial, reflecting the confidence and commitment of its founders to the company’s long-term success.

Vision of Concord Biotech Limited

Concord Biotech Ltd envisions becoming a global leader in the biopharmaceutical industry. The company aims to achieve this through innovation and a solid commitment to quality. Its vision is to set new benchmarks in developing and manufacturing Active Pharmaceutical Ingredients (APIs) and finished formulations.

The company focuses on creating value for its stakeholders. This includes customers and the communities it operates. Concord Biotech believes in building long-term relationships based on trust and mutual benefit.

Sustainability is at the core of Concord Biotech’s vision. The company is committed to reducing its environmental footprint through eco-friendly practices. This includes using renewable resources and promoting energy efficiency.

Innovation drives the company’s vision. Concord Biotech invests heavily in research and development to stay ahead of industry trends. The goal is to improve product quality and introduce new, innovative solutions continuously. The company believes that innovation is key to maintaining a competitive edge and meeting the evolving needs of the healthcare sector.

Customer satisfaction is a key aspect of the company’s vision. Concord Biotech aims to exceed customer expectations with its products and services. The company believes in understanding customer needs and providing tailored solutions. This customer-centric approach helps in building strong, long-term relationships.

The company also envisions expanding its global footprint. Concord Biotech aims to reach new markets and establish a solid international presence. Its vision includes becoming a preferred partner for pharmaceutical companies worldwide. The company plans to achieve this through strategic partnerships and collaborations.

Employee development is another important aspect of the vision. Concord Biotech aims to create a supportive and inclusive work environment. The company believes in nurturing talent and providing growth opportunities. This approach helps in building a motivated and skilled workforce.

The company also focuses on community engagement. Concord Biotech aims to contribute positively to the communities where it operates. This includes supporting local initiatives and promoting social responsibility. The company believes in giving back to society and making a difference.

Concord Biotech envisions leveraging technology to enhance its operations. The company aims to adopt advanced technologies to improve efficiency and productivity. This includes using automation and digital tools to streamline processes. The vision is to create an innovative and efficient manufacturing environment.

The company also aims to maintain high standards of corporate governance. Concord Biotech believes in transparency and ethical business practices. Its vision includes building trust with stakeholders through responsible management. The company aims to uphold integrity in all its operations.

Concord Biotech’s vision includes being a leader in quality assurance. The company aims to implement rigorous quality control measures. This ensures that all products meet the highest standards of safety and performance. The vision is to deliver reliable and high-quality products to customers.

The company also focuses on continuous improvement. Concord Biotech aims to review and enhance its processes regularly. The vision includes adopting best practices and staying updated with industry advancements. This helps in maintaining operational excellence.

Concord Biotech’s vision includes achieving financial growth and stability. The company aims to deliver consistent returns to its shareholders. Its vision includes strategic investments and prudent financial management. The company believes in creating long-term value for its stakeholders.

FAQ’s

What is the share price of Concord Biotech Ltd today?

Concord Biotech Ltd share price as on 22 Jan 2025 is ₹ 2120.55

What is the Market Cap of Concord Biotech Ltd?

The market cap of Concord Biotech Ltd stock is ₹22,601.81 Cr.

What is the PE Ratio of Concord Biotech Ltd?

The Price to Earnings (P/E) Ratio of Concord Biotech Ltd is 52.25

What is the PB Ratio of Concord Biotech Ltd?

The Price to Book (P/B) Ratio of Concord Biotech Ltd is 10.44

What is the 52 week high of Concord Biotech Ltd Share Price?

The 52 week high of Concord Biotech Ltd share price stands at ₹2,664

What is the 52 week low of Concord Biotech Ltd Share Price?

The 52 week low of Concord Biotech Ltd share price stands at ₹1,327.05

Get started with us today and
start building your wealth journey